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Osteoprotegerin Ligand Is a Cytokine
that Regulates Osteoclast Differentiation
and Activation
evidence suggests that an unidentified osteoclasto-
genic factor regulates terminal osteoclast development
and activation (Horton, 1972; Fuller et al., 1991; Lee et
al., 1991; Hentunen et al., 1994), a protein candidate for
this factor has not been identified.
D. L. Lacey,2 E. Timms,1 H.-L. Tan,2
M. J. Kelley,3 C. R. Dunstan,2
T. Burgess,4 R. Elliott,1 A. Colombero,1
G. Elliott1 S. Scully,2 H. Hsu1
J. Sullivan,5 N. Hawkins,3 E. Davy,3
C. Capparelli,2 A. Eli,2 Y.-X. Qian,5 Osteoprotegerin (OPG) is a naturally occurring se-
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G. Senaldi,2 J. Guo,2 J. Delaney,6 receptor family (Simonet et al., 1997). Administration of
OPG in vivo inhibits osteoclastogenesis and associatedand W. J. Boyle1,7
1Department of Cell Biology bone resorption and blocks the pathological increase
in osteoclast numbers and activity seen in animal mod-2Department of Pathology
3Department of Protein Chemistry els that mimic osteopenic disorders in humans (Simonet
et al., 1997). We hypothesized that OPG might neutralize4Department of Mammalian Cell Molecular Biology
5Department of Bacterial Expression a factor that stimulates osteoclast development (Simo-
net et al., 1997), thus inhibiting osteoclast maturation.6Department of Process Science
Amgen, Inc. Utilizing expression cloning,we have identified a poly-
peptide ligand for OPG (OPGL), a member of the TNFOne Amgen Center Drive
Thousand Oaks, California 91320-1789 family of cytokines that exists in transmembrane and
soluble (cleaved) forms. OPGL in vitro activates mature
osteoclasts and modulates osteoclast formation from
bone marrow precursors in the presence of CSF-1 butSummary
without the need for vitamin D3 and stromal cells. We
demonstrate that it binds to the surface of osteoclastThe ligand for osteoprotegerin has been identified, and
progenitors in CSF-1±treated bone marrow. Recombi-it is a TNF-related cytokine that replaces the require-
nant soluble OPGL is a potent inducer of bone resorptionment for stromal cells, vitamin D3, and glucocorticoids
in vivo. These data confirm our model in which OPGLin the coculture model of in vitro osteoclastogenesis.
and OPG act as positive and negative regulators of os-OPG ligand (OPGL) binds to a unique hematopoeitic
teoclast development.progenitor cell that is committed to the osteoclast
lineage and stimulates the rapid induction of genes
that typify osteoclast development. OPGL directly acti- Results
vates isolated mature osteoclasts in vitro, and short-
term administration into normal adult mice results in Identification of OPGL
osteoclast activation associated with systemic hyper- The biologically active domain of OPG is likely to interact
calcemia. These data suggest that OPGL is an osteo- with a TNF family member while negatively regulating
clast differentiation and activation factor. The effects osteoclastogenesis in vitro and in vivo. All known mem-
of OPGL are blocked in vitro and in vivo by OPG, sug- bers of the TNF family with one exception are type II
gesting that OPGL and OPG are key extracellular regu- transmembrane proteins expressed on the cell surface.
lators of osteoclast development. We used recombinant OPG-Fc fusion protein as an im-
munoprobe to screen for OPG-binding proteins on the
surface of various cell lines and primary hematopoieticIntroduction
cells. The murine myelomonocytic cell line 32D was
found to express a surface molecule, which could beBone remodeling is a normal process that involves the
detected with both the mouse OPG [22-194]-Fc andresorption of bone by osteoclasts and the synthesis of
human OPG[22-201]-Fc fusion proteins (Figure 1A). Sec-bone matrix by osteoblasts. Osteoclasts are specialized
ondary antibody alone did not bind to the surface ofmonocyte/macrophage family members that differenti-
32D cells, nor did purified human IgG1 Fc, indicatingate from hematopoietic precursors (Suda et al., 1992)
that binding of the OPG-Fc fusion proteins was due tothat appear to stem from a common monocyte precur-
the OPG N-terminal moiety. A plasmid cDNA expressionsor. Mature osteoclasts can be formed in vitro from bone
library was constructed from 32D cell mRNA and arrayedmarrow and spleen cells, a process that is facilitated by
into pools of 1000 clones. Individual pools were trans-the presence of vitamin D3 and stromal cells (Takahashi
fected into COS7 cells and then stained with the humanet al., 1988). Terminal differentiation in this lineage is
OPG [22-201]-Fc fusion protein. One positive pool wascharacterized by acquisition of mature phenotypic mark-
identified and subdivided by sequential rounds of sibers, such as the calcitonin receptor, tartrate resistant
selection yielding a single plasmid clone, 32D-F3. Theacid phosphatase (TRAP), integrin avb3, morphological
32D-F3 plasmid DNA was then transfected into COS7conversion into large multinucleated cells, and the ca-
cell cultures and then immunostained with either humanpacity to form resorption lacunae on bone. While indirect
IgG1 Fc domain, human OPG [22-201]-Fc fusion protein,
or with HVEM/ATAR-Fc fusion protein (Hsu et al., 1997),
followed by FITC-conjugated secondary antibody. Only7 To whom correspondence should be addressed.
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Figure 1. Expression Cloning of an OPGL by Cell Surface Staining Using OPG-Fc Fusion Proteins
(A) FACS analysis of 32D cells stained with either human IgG Fc domain alone, murine OPG [22-194]-Fc, or human OPG [22-201]-Fc fusion
protein. There is a shift in the entire 32D cell population following exposure to either OPG-Fc fusion protein indicating cell-surface binding.
(B) Isolation of an expression clone from a 32D cDNA library by acquisition of OPG-Fc binding to transfected COS7 cells. Indirect immunofluores-
cent staining of COS7 cultures transfected with the 32D/F3 expression clone. Left, human IgG1 Fc fragment; middle, human OPG [22-201]-
Fc fusion protein; right, ATAR-Fc fusion protein.
(C) Alignment of the mouse opgl, human opgl, and mouse TRAIL protein sequences. The predicted transmembrane regions are in bold letters.
Leftward and rightward arrows mark N- and C-terminal boundaries of the stalk region of the extracellular domain of OPGL. Descending
arrowheads mark vicinity of cleavage sites determined by N-terminal sequence analysis (mouse 139, human 140, 145). OPGL residues
representing the core TNF-like domain are underlined. Dark gray lines over the C-terminal extracellular domain indicate the position of b-sheet
forming sequences (labeled B-I) of the TNF-like core (Banner et al., 1993). Below this region is a consensus TNF profile indicating core region
homology to TNF family members.
the OPG-Fc fusion protein bound to the COS7/32D-F3 a type II transmembrane protein with a short N-terminal
intracellular domain and a longer C-terminal extracellu-cells (Figure 1B), indicating 32D-F3 encoded an OPG-
binding protein displayed on the surface of expressing lar domain (Figure 1C). The C-terminal region is com-
prised of two domains: a stalk region extending fromcells.
The 32D-F3 clone contained a long open reading leucine 70 to glycine 157, and the active ligand moiety
extending from lysine 158 to the C terminus (see below).frame in the appropriate orientation to utilize the CMV
promoter region to direct expression of a 316 amino This region is predicted to contain all 10 b-sheet forming
sequences present in all known TNF-related proteinsacid gene product in mammalian cells (data not shown)
termed OPGL (Figure 1C). A plasmid clone of putative (Figure 1C) (Banner et al., 1993).
human opgl cDNA was isolated from a lymph node cDNA
library. Translation of the human opgl cDNA sequence OPGL Specifically Bind Biologically Active OPG
To show that the 32-D F3 clone encodes an authenticencoded a 317 aa polypeptide that is approximately
87% identical to murine OPGL, indicating that this protein ligand for OPG, we tested the ability of recombinant
transmembrane and soluble OPGL to specifically bindis highly conserved during evolution (Figure 1C). The
mouse and human OPGL sequences shown here were OPG (Figure 2A). I125-labeled human OPG [22-201]-Fc
(Simonet et al., 1997) was exposed to COS7 cells trans-recently reported as the proteins encoded by TRANCE
(Wong et al., 1997) and RANK ligand (Anderson et al., fected with control plasmid (pCEP4), murine opgl (pCEP4-
32D/F3), and murine TRAIL (pCEP4-TRAIL) (Figure 2B).1997). OPGL appears to be most closely related to the
apoptosis inducing cytokine, TRAIL (Wiley et al., 1995; Radiolabeled OPG bound only to cells transfected with
opgl at a half-maximal concentration of approximatelyPitti et al., 1996), shown aligned with OPGL in Figure
1C (z34% similarity). The OPGL amino acid sequence 5 nM. Competition with 1 mM unlabeled OPG completely
blocked binding of radiolabeled OPG (Figure 2B, OPGL 1contains a probable hydrophobic transmembrane do-
main between residues 49 and 69. It is predicted to be OPG).
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Figure 2. Expression and Binding Specificity of Recombinant OPGL
(A) Map of full-length wild-type and N-terminally truncated forms of recombinant OPGL. The cytoplasmic domain, transmembrane domain,
stalk region, and TNF domain are indicated along the full-length protein. L71 marks the first residue of the extracellular domain, and K158
marks the first residue of the TNF core. Dark box at the N terminus indicates the placement of a heterologous (OPG 1-21) signal peptide to
direct secretion. OPGL regions expressed and mode of expression are noted to the left. Equilibrium dissociation constants (Kd 3 1029 M)
determined by Biacore analysis are indicated at the right.
(B) Binding of I125-labeled human OPG [22-201] to COS7 cells transfected with murine opgl, murine TRAIL, or mock transfected. opgl 1 OPG
indicates I125-OPG binding to OPGL transfected cells in the presence of 1 mM unlabeled OPG.
(C) Western blot of cell extracts or conditioned media made from either mock or murine opgl-myc transfected 293 cells probed with anti-myc
peptide antisera.
(D) OPG-Fc binding to genetically engineered soluble versions of mouse opgl. Human 293 fibroblasts were transfected with murine opgl [71-
316], murine opgl [158-316], or parent expression vector pCEP4 (Mock), then metabolically labeled with 35S-methionine. Immunoprecipitates
from conditioned media using human OPG [22-201]-Fc fusion protein were analyzed by SDS-PAGE and autoradiography.
(E) Ligand blot analysis of OPG and other TNFR-related proteins. Approximately 500 ng of recombinant purified murine OPG [22-401]-Fc,
human OPG [22-201]-Fc, murine OPG [22-180]-Fc, human TNFR1-Fc, and human ATAR-Fc fusion proteins were resolved by nonreducing
SDS PAGE. Left, duplicate blot probed with I125-labeled protein A. Right, electroblots of the SDSgels probed with I125-labeled murine recombinant
OPGL [158-316].
Expression of an epitope-tagged version of full-length Based on computational analysis of OPGL, residues
71-316 were predicted to encode the extracellular do-opgl cDNA in human 293 fibroblasts results in the pro-
duction of an approximately 45 kDa cell-associated pro- main of the protein. A core TNF-like domain was de-
duced extending from amino acid residues 158-316 (Fig-tein and the release of an approximately 31 kDa soluble
C-terminal fragment into the media. Affinity purification ures 1C and 2A). A recombinant protein spanning this
region (OPGL [158-316]) was produced in Escherichiaand N-terminal sequence analysis of the soluble mouse
and human OPGL proteins indicate that they are pro- coli. I125-labeled OPGL [158-316] was exposed to several
forms of OPG, as well as two other TNFR-related controlcessed at phenylalanine 139 (mouse) and at the homolo-
gous residue in human, isoleucine 140 (Figure 1C, de- proteins that were immobilized to nylon filters after
nonreducing SDS-PAGE (Chen et al., 1995) (Figure 2E).scending arrowheads). In addition, the human form is
also processed at alanine 145. Truncated forms of mu- Radiolabeled OPGL bound to OPG [22-401] and [22-
201]-Fc fusion proteins but not to OPG [22-180], TNFR1,rine OPGL were produced in human 293 fibroblasts by
placing a heterologous signal peptide (murine OPG ATAR (Figure 2E), or soluble DR3 Fc fusion proteins
(data not shown) (Chinnaiyan et al., 1996). Various N-ter-[1-21]) in-frame with either OPGL residues 71-316 or
158-316. Both constructs produce secreted protein of minally truncated forms of OPGL were produced in E.
coli, then purified. Binding affinities of these proteins tothe appropriate size that bind to OPG-Fc fusion protein
in solution (Figure 2D), indicating that OPG can interact immobilized human OPG [22-201]-Fc were determined
by Biacore analysis (Bartley et al., 1994). Recombinantwith both soluble and membrane-bound OPGL (Fig-
ure 2B). OPGL forms beginning at residues 126, 137, and 158 all
Cell
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Figure 3. Expression of opgl in Mouse and
Human Tissues and Cells
(A) Northern blots of poly (A)1 RNA isolated
from human tissues probed with radiolabeled
murine opgl cDNA (top) or with the mouse
GAPDH cDNA (bottom). Relative molecular
mass is indicated at the left in kilobase pairs
(kb).
(B) RNase protection analysis of mRNA from
human mouse and rat sources. Left: human
osteosarcoma cells lines MG63, SaOS, and
TE85. Middle: mouse spleen, thymus, and
lymph node tissues, osteoclast coculture
(day 4), osteoblast cell line MC3T3, and stro-
mal cell line ST2. Right: rat spleen, thymus,
and lymph node tissues, and osteogenic sar-
coma cell line ROS 17.2. All assays were per-
formed with 20 mg total RNA using radiola-
beled riboprobes to fragments of opgl and
cyclophillin. Upper bands represent OPGL pro-
tected fragments, and lower bands represent
cyclophillin protected fragments (control).
(C±J). In situ hybridization of mouse lymphoid
tissues to localize expression of opgl mRNA.
Sections of spleen ([C] and [D]), thymus ([E]
and [F]), small intestine ([G] and [H]), and
lymph node ([I] and [J]) were hybridized with
antisense riboprobes to OPGL (fragment F3),
processed and stained with H and E. (C), (E),
(G), and (I) are standard light microscopic im-
ages; (D), (F), (H), and (J) are corresponding
darkfield images. Sense riboprobes gave no
signal above background.
bound to OPG with equilibrium dissociation constants the spleen (focally), thymic medulla (focally), developing
lymph nodes (diffusely), and intestinal lymphoid patchesin the 1±5 nM range (Figure 2A), indicating that recombi-
nant soluble OPGL should be useful in biologic studies. (data not shown). opgl expression in the adult was also
found in the same lymphoid tissues (Figures 3C±3J).
opgl-expressing cells in the spleen were clearly locatedPatterns of OPGL Expression in Embryonic
and Adult Mouse Tissues in the whitepulp areas and cortical areas of lymph nodes
adjacent to the subcapsular sinus (Figure 3). The patternNorthern blot analysis of mouse tissues revealed a pat-
tern of expression similar to that previously shown for of opgl expression in adult thymus and intestine was
similar to that seen in the embryo.TRANCE and RANK ligand (data not shown) (Anderson
et al., 1997; Wong et al., 1997). Our analysis of human Expression of opgl in the skeleton is detected in the
primitive mesenchymal (PM) cells surrounding the carti-mRNA indicates that opgl expression is restricted to a
few tissues and is highest in the peripheral lymph nodes laginous anlagen and in hypertrophying chondrocytes
(HC) within the anlagen (Figures 4A and 4B). opgl mRNA(Figure 3A). In the mouse, bone marrow/stromal cell
coculture RNA (day 4) contained higher levels of opgl is also expressed in areas undergoing primary ossifica-
tion and modeling (diaphyseal cortex and medullarymRNA than spleen, thymus, and lymph node (Figure
3B). RNase protection assay of RNA obtained from os- area) in the developing femur (Figures 4C and 4D). In
normal adult bone, highest expression is detected inteogenic sarcoma cell lines indicated that SaOS and
ROS, but not MG63 and TE85 cells, express opgl mRNA the region of the primary spongiosa, localized to cells
associated with the metaphyseal vessels and hypertro-(Figure 3B). In addition, the osteoblastic cell line MC3T3
and the stromal cell line ST2, which supports osteoclast phic chondrocytes (Figures 4E±4G). High levels of opgl
expression are also detected in spindle-shaped mesen-development in vitro (Suda et al., 1992; Lacey et al.,
1995), also express opgl mRNA (Figure 3B). chymal cells in the metaphyseal, but not the diaphyseal,
periosteum (Figure 4H). Endochondral ossification ofSites of opgl expression were further localized by in
situ hybridization of mouse embryos and adult tissues. growth plate cartilage and modeling of the metaphysis
are two areas of robust osteoclast activity during longopgl expression in the day 15.5 embryo was localized in
Osteoclast Differentiation Factor
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Figure 4. In Situ Hybridization of Murine
Bone To Localize Expression of opgl mRNA
Sections of fetal rib (E15.5, [A] and [B]), fetal
femur (E15.5, [C] and [D]), and adult femur
([E]±[H]) were hybridized with antisense ribo-
probes to opgl, processed, and then stained
with H and E. In fetal cartilaginous rib anla-
gen, opgl transcripts are seen in the primitive
mesenchyme (PM) and hypertrophic chon-
drocytes (HC). In the fetal femur, OPG tran-
scripts are detectable in the areas of ossifica-
tion including the diaphyseal bony collar and
medulla where bone formation and remodel-
ing occur initially in skeletal development. In
the growing mouse, the opgl signal is promi-
nent in the metaphyseal side of the growth
plate (G) and metaphyseal perisosteum (H).
In (G), the arrowheads denote hypertrophic
chondrocytes that express opgl message. In
(H), the arrows denote OPGL expression in
mesenchymal periosteal cells, perhaps os-
teoblasts.
bone growth. The skeletal pattern of expression shown an ED50 of approximately 1 ng/ml (Figure 5A). In the
presence of CSF-1 alone, essentially no TRAP positiveis consistent with a local role for OPGL in bone metab-
olism. cells are detected, and the cells present are predomi-
nantly mononuclear (Figure 5A, upper right micrograph).
In contrast, when both CSF-1 and OPGL are added to-The OPGL Is an Osteoclast Differentiation Factor
gether, numerous TRAP-positive multinucleated cellsWe previously reported that OPG blocked osteoclast
are apparent (Figure 5A, lower right micrograph). Thedifferentiation from hematopoietic precursors in the mu-
number of osteoclasts observed per well (96-well plate)rine osteoclast coculture model (Simonet et al., 1997).
in the presence of both CSF-1 (30 ng/ml) and OPGL (100Recombinant murine OPGL was tested in the coculture
ng/ml) was 341 6 20 (mean 6 SD), whereas with CSF-1model consisting of bone marrow cells and stromal cells
alone, no osteoclasts developed. OPG inhibited this ef-cultured in media containing dexamethasone and 1,25
fect in a dose-dependent manner (Figure 5A).(OH)2 vitamin D3. Stromal cells provide CSF-1 in this
Bone marrow cultures were established on bovinesystem (Suda et al, 1992). OPGL was found to enhance
cortical bone slices and treated with either CSF-1 (30osteoclast formation with an ED5O of approximately 1
ng/ml), OPGL (100 ng/ml), or both for 6 days, and theng/ml (data not shown), and OPG blocked these effects.
formation of resorption lacunae was subsequently as-Osteoclasts and osteoclast precursors are members
sessed. Scanning electron micrographs of these cul-of the monocyte/macrophage lineage and express the
tures are shown in Figure 5B. CSF-1 alone produced acellular receptor for the lineage-specific colony factor
carpet of small mononuclear cells (Figure 5B, upper leftCSF-1 (Suda et al., 1992). The effects of OPGL on osteo-
panel). After removal of the cells, no resorption lacunaeclast differentiation of CSF-1±stimulated bone marrow
were detected (lower left panel). In cultures treated withcells were assessed using the TRAP solution assay and
OPGL alone, a few sparse cells were detected with noTRAP cytochemistry (Simonet et al., 1997). OPGL in-
creased TRAP activity in bone marrow cultures co- visible lacunae seen after cell removal (5B, middle pan-
els). However, the combination of CSF-1 and OPGL to-treated with CSF-1 in a dose-dependent manner, with
Cell
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Figure 5. Characterization of Osteoclast De-
velopment from Bone Marrow Precursors In
Vitro in the Presence of CSF-1, Murine OPGL
[158-316], and OPG [22-201]-Fc Fusion
Protein
(A) Osteoclast development from mouse bone
marrow cells cultured with CSF-1 (30 ng/ml)
and various concentrations of OPGL [158-
316] and OPG as measured by TRAP solution
assay. A405 denotes absorbance at 405 nm.
Data are presented as mean 6 SD, n 5 3.
The right panels show representative photo-
micrographs (203 objective) of TRAP stained
cultures treated with CSF-1 alone (30 ng/ml),
or CSF-1 and OPGL [158-316] (100 ng/ml).
(B) Scanning electron micrographs of bone
marrow cells cultured on bone slices in the
presence of CSF-1 (30 ng/ml) (left panels),
OPGL [158-316] (100 ng/ml) (middle panels),
or both (right panels) after 6 days in culture.
Upper panels, before removing cells; lower
panels, after removing cells. Osteoclasts and
resorption lacunae indicated by red and yel-
low arrows, respectively.
(C) RNase protection assays for phenotypic
markers of osteoclast differentiation in bone
marrow cells cultured in the presence of
CSF-1 (30 ng/ml) with (1) and without (2)
OPGL [158-316] (20 ng/ml). RNA was har-
vested on the day indicated and analyzed us-
ing probes for calcitonin receptor (CTR), b3
integrin (b3 Int), c-fms, cathepsin K (CathK),
TRAP, c-src, and PU.1 mRNA.
gether stimulates development of numerous large os- also induced osteoclast formation in cultures of hu-
man peripheral blood mononuclear cells, indicating thatteoclasts (Figure 5B, upper right panel) that are attended
by small mononuclear cells. Removal of the cell layer this effect of OPGL is not species restricted (data not
shown).revealed the presence of numerous large resorption la-
cunae in the cortical bone (Figure 5B, lower right panel). The process of osteoclast differentiation from precur-
sor cells involves the expression of proteins that to-Marrow cultures were treated with a variety of cyto-
kines (IL-3, IL-6, and IL-11) or hematopoietic factors gether identify cells of osteoclast lineage, including cell
surface receptors (calcitonin receptors, avb3 integrin,(SCF, G-CSF, MDGF, and GM-CSF) to determine whether
they could also collaborate with OPGL (data not shown). c-fms), lysosomal enzymes (TRAP, cathepsin K), intra-
cellular signaling molecules (c-src), and transcriptionOnly CSF-1 supported the osteoclast differentiation ef-
fects of OPGL based on the TRAP solution and cyto- factors (PU.1). Time course studies of cells treated with
CSF-1 and OPGL show that mRNA for the b3 integrin,chemical assays described above. Furthermore, OPGL
alone does not support bone marrow cell growth (Figure TRAP, cathepsin K, and c-src are elevated in the pres-
ence of OPGL as early as 2 days following culture initia-5B), further establishing CSF-1 as necessary but not
sufficient for osteoclast development (Suda et al, 1992). tion (Figure 5C). The levels of calcitonin receptor mes-
sage are not elevated by OPGL early after cultureHere, we report that robust osteoclast formation in mice
occurred in defined media in the absence of stromal initiation, but the difference between control and OPGL-
treated cultures clearly widen by day 4. The levels ofcells, dexamethasone, and 1,25 (OH)2 vitamin D3. OPGL
Osteoclast Differentiation Factor
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c-fms and PU.1 do not differ significantly between
OPGL-treated and control cultures. Bone marrow prolif-
eration and survival does not occur in the absence of
added CSF-1, so the effects of OPGL alone on gene
regulation in bone marrow cells could not be assessed.
Taken together with the cell culture data, these findings
conclusively establish OPGL as a potent osteoclast dif-
ferentiation factor.
Osteoclast Progenitor Cells Are Identified by OPGL
The phenotype of colony forming cells in isolated bone
marrow stimulated by CSF-1 and OPGL was determined
in colonies formed in semisolid agar by TRAP staining,
as this enzyme is highly induced early during osteoclast
differentiation (Figure 5C). OPGL increased the number
of TRAP positive colonies 3- to 4-fold when used in
combination with CSF-1 to stimulate the bone marrow
(Figure 6A). No colonies are formed from the marrow in
the absence of CSF-1 (data not shown), further under-
scoring the inability of OPGL to serve as a growth factor.
About 1/31,000 bone marrow cells form TRAP-positive
colonies when the stimulus is CSF-1 alone. The fre-
quency of TRAP-positive colonies increases in the pres-
ence of both CSF-1 and OPGL to about 1/9000 bone
marrow cells. About 25% of all colonies formed in the
presence of both factors are TRAP-positive. The effect
of OPGL on TRAP positive colony formation is dose-
dependent (Figure 6B) and similar to the range that ef-
fectively drives osteoclast development (Figure 5A).
While we have not directly demonstrated that the cells
in the TRAP-positive colonies form osteoclasts, these
data show that OPGL modulates the developmental fate
of myeloid colonies that arise in the presence of CSF-1
in a manner consistent with early osteoclast differenti-
ation.
The bioactivity of OPGL on CSF-1±treated marrow
cells suggests that it binds directly toosteoclast progen-
itor cells. Osteoclast precursor cells within bone marrow
were identified and characterized by binding to fluores-
cein-OPGL (FITC-OPGL) (Figure 6C). The differentiation
capacity of the FACS-sorted OPGL binding (R2) and
nonbinding (R1) was determined by treating them with
CSF-1 and OPGL in culture. R1 cells at days 1 and 2
exhibited primarily a rounded, nonadherent morphol-
ogy, whereas cells that bind FITC-OPGL (R2) displayed
a distinct adherent, fibroblast-type appearance (data
not shown).After 3 days of culture, R2 cells have become
very large with dendritic projections and ruffled edges,
with a small percentage of the cells being multinuclear.
By day 4 of culture, R2-positive cells are extremely large
Figure 6. Bone Marrow Colony Assay and FACS Isolation of Osteo- (up to 150 mM diameter) with convoluted membranes
clast Progenitors Using FITC-OPGL
(A) Bone marrow cells (5 3 105 cells) were cultured for 6 days in
semisolid agar in the presence of CSF-1 (30 ng/ml) and OPGL [158-
316] (20 ng/ml). Following TRAP staining, the colonies were counted (C) FACS analysis using a FITC-OPGL probe of bone marrow cells
based on their TRAP staining characteristics as shown in the photo- treated with CSF-1(30 ng/ml) and OPGL [158-316] (20 ng/ml) for 24
micrographs; totally negative (2), weakly positive (1/2), or strongly hr. R1 denotes the negative population, and R2 denotes the posi-
positive (1). The data from three experiments were pooled and the tively staining population.
data are presented as the mean 6 SD, n 5 13±15/group. Asterisk (D) Culture phenotype of bone marrow cells sorted as in (C). The
denotes p , 0.0001; Double asterisks denote p , 0.005, t test. No R1 and R2 populations from (C) were placed back into culture with
colonies were detected in the absence of CSF-1. CSF-1 (15 ng/ml) and OPGL [158-316] (10 ng/ml) and stained using
(B) Bone marrow cells (5 3 105 cells) were cultured for 7 days in FITC-phalloidin/propidium iodide (upper panels) and TRAP cyto-
semisolid agar in the presence of CSF-1 (30 ng/ml) and the indicated chemistry (lower panels), respectively, after 4 days in culture (203
concentrations of OPGL [158-316]. TRAP-positive colony counts magnification). Note that the R2 population develops numerous
(mean 6 SD, n 5 5/group) versus OPGL levels are shown. TRAP-positive multinucleated cells.
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5-fold molar excess of OPG (Figure 7B). The basal level
of osteoclast resorptive activity was not altered by the
addition of OPG,suggesting that OPGL may not regulate
basal osteoclast activities in this resorption system. The
number of mature osteoclasts remaining at the end of
the experiment did not vary between the different condi-
tions, indicating that OPGL did not act as an osteoclast
survival factor or enhance adhesion in the time frame
analyzed.
OPGL Administration Stimulates Bone
Resorption in Mice
Mice injected subcutaneously with recombinant OPGL
rapidly developed significant increases in blood ionized
calcium (hypercalcemia) with trends seen as early as 1
day after the initiation of twice daily injections (Figure
8A). The severity of hypercalcemia was dependent on
the dose level and time of treatment over the 3 days of
treatment. At the highest dose level (50 mg, twice a day),
animals showed extreme hypercalcemia by the third day
(Figure 8A). The coadministration of OPG significantly
reduced the hypercalcemic effects of OPGL (Figure 8B).
Histomorphometric and radiographic assessment of
tibiae from the OPGL and control-treated animals after
3 days of treatment revealed a reduced bone volume in
the proximal tibiae of OPGL-treated mice compared to
saline-treated animals (data not shown). The number of
Figure 7. OPGL Activates Mature Osteoclasts To Resorb Bone osteoclasts in the control and OPGL-treated animals
Mature rat osteoclasts were isolated from postnatal day 2 rat pups was similar with no changes seen at any OPGL dose
and cultured on bovine bone slices (n 5 4 /condition) for 24 hr at level, despite the presence of marked hypercalcemia
378C. Osteoclasts were defined as TRAP-positive and containing
(Figure 8C). However, the size and nuclearity of the os-more than three nuclei, and resorption pits were visualized by tolu-
teoclasts in the OPGL-treated group significantly ex-idine blue staining. The number of osteoclasts and pits were
ceeded the controls, and these increases were dose-counted, and the data expressed as the average number of pits/
osteoclast 6 SD. In (A), a dose response assay was performed using related (Figure 8C). The effect on cell size was the most
the various concentrations of OPGL [158-316] shown. In (B), the pit pronounced effect of OPGL, with osteoclast area more
assay was performed using media alone (control), OPG [22-201]-Fc than doubling in OPGL-treated animals. Photomicro-
(130 ng/ml), OPGL (10 ng/ml), and the combination of both.
graphs showing the histology of these changes (Figures
8D and 8E) demonstrate the prominence of these effects
on osteoclasts following treatment with OPGL.containing numerous dendritic processes (Figure 6D,
right panels). The majority of the cells are multinuclear,
with as many as 10 distinct nuclei visible. All of the cells Discussion
capable of forming osteoclasts in vitro are contained
only within the R2 population (data not shown). In con- OPG selectively inhibited osteoclast differentiation and
function in vitro and in vivo (Simonet et al., 1997). Fromtrast R1 cells still appear rounded at day 4 with few
adherent cells observed (Figure 6D, left panels). this we reasoned that OPG must interact with a TNF-
related family member while mediating its effects, and
we sought to identify a putative cell source producingOPGL Activates Mature Osteoclasts
To Resorb Bone In Vitro this factor. We have identified and expression cloned an
OPGL using OPG as a probe. opgl mRNA is expressed atThe rapid increases in bone density observed in neonate
mice treated with OPG suggest that it not only blocks high levels in growing and modeling bones and in the
murine osteoclast coculture system, both of which ex-osteoclast development but may also regulate the func-
tion of mature, preexisting osteoclasts (Simonet et al., hibit or favor the development of active osteoclasts.
Furthermore, opgl mRNA is expressed in a number of1997). To test this idea, we isolated mature osteoclasts
from neonatal rats and placed them onto cortical bone rodent and human cell osteoblast cell lines. These find-
ings strongly suggest that OPG and OPGL are likely toslices to quantitatively measure bone resorption in the
presence and absence of OPGL. No CSF-1 was used interact in the bone microenvironment during regulation
of osteoclastogenesis and that OPGL may be a pivotalin these experiments, as these cells exhibit adequate
survival in culture for this short period. Our results show coupling factor produced by osteoblasts.
The biological activity of OPGL in vitro and in vivo hasthat OPGL stimulates mature osteoclast activity in vitro
with positive effects seen at 1 ng/ml, maximizing at 10 been extensively characterized. We have shown, when
combined with CSF-1, OPGL stimulates osteoclast de-ng/ml (Figure 7A). The strong activation of mature osteo-
clasts was completely inhibited by the addition of a velopment, increases TRAP positive colony formation,
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Figure 8. OPGL Administration Causes Hy-
percalcemia and Osteoclast Activation In
Vivo
(A) Mice were injected with various amounts
of OPGL [158-316] twice daily for 3 days with
ionized blood calcium levels determined ev-
ery morning 3 hr following the first injection.
Data represent the mean 6 SD , n 5 4. Aster-
isk denotes p , 0.05, compared to control.
(B) Mice were injected with OPGL [158-316]
at the indicated amounts 6 OPG [22-201]-
Fc (50 mg/day). On the second day, ionized
blood calcium were determined and are pre-
sented as the mean 6 SD, n 5 4. An asterisk
and pound sign denote p , 0.05, compared
to control or OPGL [158-316] alone, respec-
tively.
(C) Histomorphometry was performed on tib-
iae from animals sacrificed at the end of 3
days of treatment with the indicated OPGL
[158-316] doses. The number of osteoclasts/
bone perimeter (NOc/BPm), mean osteoclast
area (OcAr/Noc), and osteoclast nuclearity
(NNc/NOc) were determined. The results rep-
resent the mean 6 SD, n 5 4. Asterisk de-
notes p , 0.05, compared to control.
(D and E) Photomicrographs (403 objective
for both) of TRAP-stained sections of osteo-
clasts on bone from control (D) and OPGL (E)
injected animals. The calibration bar repre-
sents 25 mm and applies to both (D) and (E).
and activates mature, preexisting osteoclasts. Both os- of OPGL capable of inducing hypercalcemia (1 mg/kg/
day), FACS analysis (CD3, B220, CD4, CD8) showed noteoclasts and bone marrow osteoclast progenitors were
identified as cell types that OPGL binds. Soluble recom- striking effects of OPGL on peripheral blood, spleen, or
lymph node lymphocyte populations (data not shown).binant OPGL is a potent factor, with an ED50 for all of
these activities in the range of 1 ng/ml (z60 pM). Admin- OPGL tested in concentrations ranging from 0.01 to 100
mg/ml failed tostimulate theproliferation of lymphocytesistration of OPGL to normal mice rapidly causes hyper-
calcemia through osteoclast activation. All of the in vitro from peripheral blood or lymph node (data not shown).
In addition, OPGLat the same concentration range failedand in vivo effects of OPGL are counteracted by the
addition of OPG, both validating the means of OPGL to alter lymphocyte proliferation when the stimulus was
allogeneic spleen cells in mixed leukocyte cultures (datadiscovery and the role of OPG as a modulator of osteo-
clast development and activity. Further evidence of the not shown). The role of OPGL/TRANCE/RANKL on in
vivo immunomodulation remains to be determined, andimportance of OPG as a regulator of bone metabolism
through its effects on osteoclasts has been recently disruption of the OPGL gene in mouse should provide
important information.confirmed through generation of OPG knockout mice.
These animals have markedly increased osteoclast ac- Previous attempts to identify and characterize an os-
teoclast differentiation factor have resulted in descrip-tivity and severe osteoporosis characterized by de-
creased trabecular bone mass and cortical thinning (Bu- tions of various crude activities, but specific molecules
for these effects have not been identified (Horton, 1972;cay et al., submitted). We conclude that an important
physiologic role of OPGL is to regulate osteoclast func- Abe et al., 1986; Fuller et al., 1991; Lee et al., 1991;
Yoneda et al, 1993; Hentunen et al., 1994). In the pres-tion and, indirectly, bone mass.
As these studieswere in progress, two reports emerged ence of CSF-1, OPGL rapidly induces the process of
osteoclast differentiation through increases in expres-that characterized invitro immunologic activities for pro-
teins identical to what we call OPGL, suggesting that it sion of genes that typify the osteoclast phenotype, pre-
sumably at the transcriptional level. The cell signalingalso is likely to play a role in T cell activation and antigen
presentation in vitro (Anderson et al., 1997; Wong et al., events induced by OPGL that are intrinsic to osteoclast
progenitors are as yet undefined. One potential cell sur-1997). We have tested the effects of OPGL in vivo and
in vitro for an indication of potential general immuno- face receptor for OPGL appears to be RANK, a novel
TNF receptor family member that was cloned from amodulatory activity. After a 7 day treatment with a dose
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293 fibroblasts, and cell extracts and conditioned media were ana-dendritic cell library (Anderson et al., 1997). While this
lyzed by western blotting using anti-myc antibodies. Bacterial ex-receptor is indeed present on the OPGL sorted bone
pression plasmids were constructed to express N-terminally trun-marrow cells that differentiate into osteoclasts (E. T.
cated forms of murine OPGL (spanning residues 75-316, 126-316,
and W. J. B., unpublished data), it has a wide tissue 137-316, or 158-316) in E. coli. All of these forms of OPGL are
distribution, and we have not found evidence for NF- preceded by an artificial methionine start codon. E. coli containing
the various expression plasmids were induced during fermentation,kB activation during ligand-induced osteoclastogenesis
and the OPGL products were purified from the soluble bacterial(data not shown). Determining the identity and nature
fraction using anion and cation-exchange chromatography. Recom-of the receptor on osteoclast progenitor cells should
binant murine OPGL [158-316] or human OPG 22-[201]-Fc proteinshelp resolve the precise signaling events involved in
were radiolabeled with I125 using Bolton-Hunter reagent (Amersham,
OPGL-induced osteoclastogenesis. Arlington Heights, IL.). Fluorescent labeling was performed by incu-
In summary, a model for the regulation of bone mass bation of recombinant murine OPGL [158-316] with 6-fluorescein-
5-(and 6) carboxyamido hexanoic acid succinimidyl ester (Molecularis proposed whereby OPGL effects a ligand-stimulated
Probes, Eugene, OR) at a 1:6 molar ratio for 12 hr at 48C. FITC-pathway of differentiation, involving the commitment
labeled OPGL [158-316] was further purified by gel filtration chroma-and terminal differentiation of the osteoclast lineage(s).
tography.OPG is, therefore, a secreted antagonist of this pathway
and can neutralize and/or sequester a key osteoclast OPGL Binding Assays
differentiation and activation factor that normally binds COS7 cells were lipofected with plasmid expression vector pCEP4,
to an osteoclast surface receptor. These findings have pCEP4-murine opgl, or pCEP4-murine TRAIL and then cultured for
48 hr. Cell cultures were washed once with ice-cold DMEM con-great impact on how we view the function of the osteo-
taining 10 mM HEPES (pH 7.0), 1 mg/ml BSA (binding buffer), andclast during development, adult bone remodeling, and
various concentrations of I125 human OPG [22-201]-Fc fusion proteinpresenile osteoporosis and lytic bone diseases. They
(0.1-50 nM) in 250 ml of binding buffer were added and incubatedalso suggest that key extracellular factors that regulate
on ice for 4 hr. To determine nonspecific binding, opgl-transfected
osteoclast development have been defined, allowing for cells were also treated similarly in the presence of 1 mM unlabeled
the further in vitro and in vivo characterization of this native murine OPG [22-401]. The binding solution was removed,
cells washed, and then lysed with 1M NaOH and radioactivity mea-important hematopoietic lineage.
sured. Human 293 fibroblast cells were transfected with expression
vector containing opgl sequences engineered to express secreted
forms of the protein. Cell cultures lipofected with pCEP4, pCEP4-Experimental Methods
murine opgl [71-316], or murine opgl [158-316] were metabolically
labeled, and the conditioned media immunoprecipitated as de-Expression Cloning of OPGL
scribed (Simonet et al., 1997) using human OPG [22-210]-Fc fusionCell lines were screened for the presence of OPGL by indirect immu-
protein (1 mg/ml) as antibody. Ligand blotting was performed asnofluorescence or FACS analysis after staining with mouse OPG
described (Chen et al., 1995). Approximately 500 ng of OPG, TNFR1-[22-194]-Fc or human OPG [22-201]-Fc fusion proteins (Simonet et
Fc, or ATAR-Fc (Hsu et al., 1997) fusion proteins were probed withal., 1997), followed by phycoerythrin-conjugated goat F(ab') anti-
either a 1.5 mg/ml solution of I125-OPGL (5.8 3 1013 cpm/mmol) orhuman IgG secondary antibody (Southern Biotechnology Associ-
I125-protein A (Amersham, Co., Arlington Heights, Il) for 4 hr at roomates Cat. #2043-09). The cells were then analyzed by immunofluores-
temperature. Blots were washed with PBS, then exposed to X-raycent microscopy or by FACS using a Becton Dickinson FACscan
film (Kodak) using an intensifying screen for 3 hr at 2708C. Recombi-(San Jose, CA). A directional, oligo-dT primed cDNA library was
nant human OPG [22-201]-Fc fusion protein was immobilized byprepared from 32D cell line mRNA and ligated into the mammalian
passing a 70 mg/ml solution (10 mM acetate buffer [pH 4.0]) over aexpression vector pcDNA 3.1(1) (Invitrogen, San Diego, CA) as pre-
CM5 biosensor chip (Pharmacia, Piscataway, NJ), and unreactedviously described (Simonet et al., 1997). The library was arrayed into
residues were then blocked with 1 M ethanolamine as previouslypools containing approximately 1000 clones, and plasmid DNA from
described (Bartley et al., 1994). For kinetic studies, recombinanteach was prepared using the Qiagen Qiawell 96 Ultra Plasmid Kit
murine OPGL [75-316], [126-316], [137-316], and [158-316] were(Cat. #16191). DNA from individual pools were lipofected into COS7
diluted into buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 0.005%cultures (Simonet et al., 1997). After 48 hr, cultures were washed,
Surfactant P20, 10 mg/ml BSA, and50 mg/ml dextran), then individu-then exposed to PBS-FBS solution containing 5 mg/ml of human
ally passed over the biosensor chip at ligand concentrations of 1,OPG[22-201]-Fc fusion for 1 hr at RT. The cells were washed and
2, 4, 8, and 16 mg/ml. Samples were injected at flow rates of 5, 10,then fixed in PBScontaining 2% paraformaldehyde and 0.2% glutar-
and 20 ml/min to reduce mass transport limitation. Results were fitaldehyde at RT for 5 min, rinsed once with PBS-FCS, and incubated
into a 1-to-1 binding model using BIAevaluation software (BIACOREfor 1 hr at 658C while immersed in PBS-FCS solution to inactivate
AB), and equilibrium dissociation constants (Kd) were calculated.endogenous phosphatase activity. Cultures were treated with an
alkaline-phosphatase conjugated goat anti-human IgG (Fc specific)
mRNA Analysisantibody (SIGMA Product # A-9544), and immune complexes were
Multiple human tissue northern blots (Clontech, Palo Alto, CA) weredetected by assaying for alkaline phosphatase activity using the
probed with a 32P-dCTP (Amersham, Arlington Heights, IL) labeledFast Red TR/AS-MX Substrate Kit (Pierce, Cat. #34034). The 32D-
32D-F3 restriction fragment to detect transcript size and to deter-F3 clone isolated above contained an approximately 2.3 kb cDNA
mine patterns of expression, as previously described (Simonet et al.,insert, which was sequenced and analyzed as previously described
1997). Total RNA was analyzed by RNase protection using probes(Simonet et al., 1997).
derived from the mouse b3 integrin, calcitonin receptor, cathepsin K,
c-fms, PU.1, c-src, TRAP, and opgl cDNA sequences. Radiolabeled
antisense transcripts were synthesized from DNA templates usingExpression and Chemical Modification of Recombinant OPGL
The murine opgl was subcloned into the mammalian expression 32P-UTP (800 Ci/mole; Amersham, Arlington Heights, IL), and RNase
protection assays were performed using the RPA II kit (Ambion,vector pCEP4 (Invitrogen, San Diego, CA) as previously described
(Simonet et al., 1997). N-terminal truncations of murine OPGL were Inc. Austin, TX) and cyclophilin probes as internal controls. In situ
hybridization was performed as described (Wilcox, 1993) on forma-produced by fusing a heterologous signal peptide (murine OPG
residues 1-21) (Simonet et al., 1997) in-frame to either reside 71 or lin-fixed, paraffin-embedded sections of mouse tissues. Radiola-
beled antisense and sense control transcripts were synthesized158. The murine OPGL full-length protein was epitope-tagged at
the C terminus by fusion to the myc peptide as described (Wilson from DNA templates with 33P-UTP (1000±3000 Ci/mole; Amersham)
as the labeling isotope. Slides were counterstained with hematoxylinet al., 1997). Expression constructs were transfected into human
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and eosin (H and E, respectively) and imaged using light and dark- the data expressed as the average number of pits/cells (as defined
above) plus or minus standard deviation. All pits, whether contigu-field illumination.
ous or separated from other pits, were counted as single pits.
OPGL Induced Osteoclastogenesis In Vitro
Osteoclasts were derived from bone marrow cultures using two In Vivo Response to Recombinant OPGL
methods. In the first method, ST2 cells (Riken Gene Bank, Tsukuba Male BDF1 mice (n 5 4) aged 3±4 weeks received varying doses of
Science City, Japan, 1 3 105 cells/ml) and previously prepared non- PBS, murine OPGL for 3 days, or both OPG [22-194]-Fc and OPGL
adherent mouse bone marrow cells were combined and cultured in for 2 days. The groups receiving concurrent treatment of both OPG
96-well plates (Nunc, Naperville, IL) (Takahashi et al., 1988; Lacey and the OPGL were pretreated for 1 day with 50 mg of OPG. Animals
et al., 1995; Udagawa et al., 1996) in media supplemented with 1,25 receiving OPGL received either 1, 5, 25, or 100 mg split into two daily
(OH)2 vitamin D3 (1 3 1028 M) and dexamethasone (1 3 1027 M). In subcutaneous injections, while animals receiving OPG concurrently
the second method, nonadherent bone marrow cells (1 3 106 cells/ were given 50 mg as a single daily injection at the time of the first
ml) were cultured in the presence of murine CSF-1 (30 ng/ml, R & D OPGL injection. OPG and OPGL were injected at different subcuta-
Systems, Minneapolis, MN) and various concentrations of OPGL neous locations. Blood ionized calcium levels from retro-orbital
[158-316] in the absence of stromal cells, 1,25 (OH)2 vitamin D3, and samples were monitored 3 hr after morning injections using a blood
dexamethasone. In some experiments, the cells were cultured on ionized calcium/pH analyzer (Chiron Diagnostics #634, Norwood,
bovine cortical bone slices (Lacey et al, 1995). The presence of MA). At the study conclusion, the femur and tibia were removed,
generated osteoclasts was evaluated by TRAP solution assay and fixed in buffered zinc formalin, decalcified in formic acid, and em-
cytochemical staining as previously described (Simonet et al., 1997). bedded in paraffin. Sections taken through the midregion of the
distal femur and proximal tibia were stained for TRAP activity and
Colony Assay counterstained with hematoxylin. Histomorphometry was performed
Mouse bone marrow cells (5 3 105 cells/ml) were cultured in agar using the Osteo Measure (Osteometrics, Atlanta, GA) image analysis
(0.3 %, Bacto-agar, Difco) containing DMEM, L-asparagine (12.5 program. Measurements were made of the area just distal to the
mg/ml), DEAE dextran (50 mg/ml, Pharmacia, Uppsala, Sweden), proximal tibial growth plate in a 1 mm 3 1 mm area, not including
20% heat-inactivated fetal calf serum in 1 ml aliquots in 35 mm petri any of the growth plate. Osteoclasts were identified as TRAP-posi-
dishes. Murine recombinant CSF-1 (30 ng/ml) and the indicated tive cells adjacent to bone surfaces (Evans et al., 1979). The bone
amounts of OPGL [158-316]were placed (50 ml volume) in the dishes perimeter, osteoclast area, osteoclast number, and number of os-
prior to the addition of the agar/cell suspensions. After 7 days, the teoclast nuclei were quantitated. Results were expressed as osteo-
cultures were fixed in a citrate/acetone/formaldehyde solution and clast number per millimeter of bone perimeter (NOc/BPm), osteo-
histochemically stained for TRAP activity (Sigma, St. Louis, MO). clast area per osteoclasts (OcAr/NOc), and number of nuclei per
Only colonies containing a minimum of 50 cells were scored. The osteoclast (NNc/NOc).
air-dried stained plates were used to count colonies using TRAP
staining as a phenotypic marker, and three levels of TRAP positivity Acknowledgments
were scored (1, 1/2, 2) as shown in Figure 6A.
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GenBank Accession Numbers
The accession numbers for the mouse and human opgl sequences
reported here are AF053713 and AF053712, respectively.
